Plinabulin + Docetaxel

About BeyondSpring Pharmaceuticals

BeyondSpring Pharmaceuticals is a clinical-stage oncology company developing its lead asset, Plinabulin, a first-in-class small-molecule immune modulator. The company's strategy is centered on demonstrating Plinabulin's efficacy in improving overall survival and reducing chemotherapy side effects, particularly in non-small cell lung cancer (NSCLC). With a late-stage pipeline and a leadership team experienced in oncology development, BeyondSpring aims to secure regulatory approvals and establish its therapies as new standards of care in key global markets.

About BeyondSpring

BeyondSpring is a NASDAQ-listed biotech focused on developing plinabulin, a novel immunomodulating microtubule-binding agent, for oncology. Its primary objectives are securing approval for plinabulin to prevent chemotherapy-induced neutropenia (CIN) and demonstrating its efficacy as a combination therapy in non-small cell lung cancer (NSCLC). The company's strategy leverages a dual-mechanism platform to differentiate from standard care and targets high-value markets in the US and China. Despite a prior FDA Complete Response Letter for CIN, BeyondSpring continues to generate supportive clinical data, particularly from its Phase 3 DUBLIN-3 trial in NSCLC, to build a compelling case for global registration.

Therapeutic Areas